May. 26 at 3:56 AM
$RFL So, the trial results (96-Week) have been targeted for Q3 2026. That leaves the next 26 trading days without a known catalyst. I am aware of other subsidiary companies, one with a couple of early stage readouts in oncology, maybe? Regardless, the only tangible boost would be a positive TRANSPORT readout. Unless I’m missing something. MIPLYFFA’s approval or rejection by CHMP could move the needle some. We’ll see.
